







an Open Access Journal by MDPI

# **Hormone Therapy**

Guest Editor:

#### Dr. John Eden

Department of Reproductive Endocrinology, The University of New South Wiles, Sydney, Australia

Deadline for manuscript submissions:

closed (30 June 2012)

# Message from the Guest Editor

Dear Colleagues,

Some years ago HT was being touted as a treatment for most if not all menopausal women to treat symptoms such as hot flushes as well as a preventive agent for heart disease and osteoporosis. However, since the first publication of the results of the Women's Health Initiative (WHI) in July 2002, HT usage has declined substantially. Much of the female population is now fearful that HT usage may increase their risk of breast cancer. Around a quarter of women will have severe menopausal symptoms as they pass through the menopause transition and some will have symptoms for the rest of their lives. How safe is HRT? How should we manage women who have severe menopausal flushing for years? Which is the best method for managing genitourinary symptoms? These are some of the questions being addressed this this issue.

Dr. John Eden Guest Edtor













an Open Access Journal by MDPI

# **Editor-in-Chief**

### Prof. Dr. Amélia Pilar Rauter Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

### **Contact Us**